ASCO 2023 | Pediatric leukemia at ASCO 2023
Sarah Tasian, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, discusses updates in pediatric leukemia as shared during the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. First, Dr Tasian reports findings of a genomic study aimed to identify new predictors of relapse for standard or high-risk acute lymphoblastic leukemia (ALL). Secondly, Dr Tasian shares an update from the second safety phase results from the Children’s Oncology Group (COG) AALL1732 trial evaluating inotuzumab ozogamicin in pediatric patients with high-risk B-ALL. Finally, Dr Tasian highlights preliminary results from the first-in-child Phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed chronic myeloid leukemia (CML). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
